Activation of protein kinase G increases the expression of p21 CIP1, p27KIP1, and histidine triad protein 1 through Sp1

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5355-5362

  Cen, Bo ^a   Deguchi, Atsuko ^a,b   Weinstein, I Bernard ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HISTIDINE; HISTIDINE TRIAD PROTEIN 1; LUCIFERASE; MESSENGER RNA; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN KINASE; PROTEIN KINASE G IBETA; SERINE; SMALL INTERFERING RNA; SULINDAC SULFONE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HINT1 PROTEIN, HUMAN; NERVE PROTEIN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR SP1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL; CANCER PREVENTION; CANCER THERAPY; CELL MEMBRANE PERMEABILITY; COLON CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROMOTER REGION; PROTEIN BINDING; UPREGULATION;

BINDING SITES; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVE TISSUE PROTEINS; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; RNA, MESSENGER; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 48549098685     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6869     Document Type: Article

References (49)

1. Francis SH, Corbin JD. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 1999;36:275-328.
2. Pfeifer A, Ruth P, Dostmann W, Sausbier M, Klatt P, Hofmann F. Structure and function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol 1999;135:105-49.
3. Ruth P. Cyclic GMP-dependent protein kinases: understanding in vivo functions by gene targeting. Pharmacol Ther 1999;82:355-72.
4. Pfeifer A, Klatt P, Massberg S, et al. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J 1998;17:3045-51.
5. Hou Y, Gupta N, Schoenlein P, et al. An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett 2006;240:60-8.
6. Deguchi A, Thompson WJ, Weinstein IB. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res 2004;64:3966-73.
7. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res 2000;60:3338-42.
8. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003;4:425-9.
9. Blain SW, Scher HI, Cordon-Cardo C, Koff A. p27 as a target for cancer therapeutics. Cancer Cell 2003;3:111-5.
10. Jackson RJ, Engelman RW, Coppola D, Cantor AB, Wharton W, Pledger WJ. p21Cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res 2003; 63:3021-5.
11. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001;61:6234-8.
12. Philipp J, Vo K, Gurley KE, Seidel K, Kemp CJ. Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. Oncogene 1999;18:4689-98.
13. Topley GI, Okuyama R, Gonzales JG, Conti C, Dotto GP. p21(WAF1/Cip1) functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. Proc Natl Acad Sci U S A 1999;96:9089-94.
14. Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999;246:280-9.
15. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 α and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem 2002;277:29792-802.
16. Li Y, Dowbenko D, Lasky LA. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 2002;277:11352-61.
17. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 2001;21:5644-57.
18. Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 2002;277:9684-9.
19. Scott MT, Ingram A, Ball KL. PDK1-dependent activation of atypical PKC leads to degradation of the p21 tumour modifier protein. EMBO J 2002;21:6771-80.
20. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001;3:245-52.
21. Inoue T, Kamiyama J, Sakai T. Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 1999;274:32309-17.
22. Minami S, Ohtani-Fujita N, Igata E, Tamaki T, Sakai T. Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett 1997;411:1-6.
23. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9.
24. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997;11:1464-78.
25. Sutterluty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207-14.
26. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997;16:5334-44.
27. Brenner C. Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry 2002;41:9003-14.
28. Su T, Suzui M, Wang L, Lin CS, Xing WQ, Weinstein IB. Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis. Proc Natl Acad Sci U S A 2003;100:7824-9.
29. Li H, Zhang Y, Su T, Santella RM, Weinstein IB. Hint1 is a haplo-insufficient tumor suppressor in mice. Oncogene 2006;25:713-21.
30. Wang L, Zhang Y, Li H, Xu Z, Santella RM, Weinstein IB. Hint1 inhibits growth and activator protein-1 activity in human colon cancer cells. Cancer Res 2007;67:4700-8.
31. Weiske J, Huber O. The histidine triad protein Hint1 interacts with Pontin and Reptin and inhibits TCF-β-catenin-mediated transcription. J Cell Sci 2005;118:3117-29.
32. Weiske J, Huber O. The histidine triad protein Hint1 triggers apoptosis independent of its enzymatic activity. J Biol Chem 2006;281:27356-66.
33. Razin E, Zhang ZC, Nechushtan H, et al. Suppression of microphthalmia transcriptional activity by its association with protein kinase C-interacting protein 1 in mast cells. J Biol Chem 1999;274:34272-6.
34. Klein MG, Yao Y, Slosberg ED, Lima CD, Doki Y, Weinstein IB. Characterization of PKCI and comparative studies with FHIT, related members of the HIT protein family. Exp Cell Res 1998;244:26-32.
35. Deguchi A, Soh JW, Li H, Pamukcu R, Thompson WJ, Weinstein IB. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther 2002;1:803-9.
36. Pitari GM, Li T, Baksh RI, Waldman SA. Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells. Mol Cancer Ther 2006;5:1190-6.
37. Deguchi A, Xing SW, Shureiqi I, et al. Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. Cancer Res 2005;65:8442-7.
38. Moon EY, Lerner A. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res 2002;62:5711-9.
39. Gu M, Lynch J, Brecher P. Nitric oxide increases p21(Waf1/Cip1) expression by a cGMP-dependent pathway that includes activation of extracellular signal-regulated kinase and p70(S6k). J Biol Chem 2000;275:11389-96.
40. Ikui AE, Yao Y, Zhou P, Weinstein IB. Induction of apoptosis by sulindac sulfide in HL60 cells is enhanced by p21CiP1 or p27KiP1. Anticancer Res 2001;21:2297-303.
41. Shen TY, Winter CA. Chemical and biological studies on indomethacin, sulindac and their analogs. Adv Drug Res 1977;12:90-245.
42. Thompson HJ, Briggs S, Paranka NS, et al. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 1995;87:1259-60.
43. Soh JW, Kazi JU, Li H, Thompson WJ, Weinstein IB. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog 2007.
44. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
45. el-Deiry WS, Tokino T, Waldman T, et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995;55:2910-9.
46. Chu S, Ferro TJ. Sp1: regulation of gene expression by phosphorylation. Gene 2005;348:1-11.
47. Deniaud E, Baguet J, Mathieu AL, Pages G, Marvel J, Leverrier Y. Overexpression of Sp1 transcription factor induces apoptosis. Oncogene 2006;25:7096-105.
48. Orstavik S, Natarajan V, Tasken K, Jahnsen T, Sandberg M. Characterization of the human gene encoding the type I α and type I β cGMP-dependent protein kinase (PRKG1). Genomics 1997;42:311-8.
49. Sellak H, Yang X, Cao X, Cornwell T, Soff GA, Lincoln T. Sp1 transcription factor as a molecular target for nitric oxide- and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Iα expression in vascular smooth muscle cells. Circ Res 2002;90:405-12.